Biopharmaceutical News and Research

RSS

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

13 Aug 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, a charitable corporation of Massachusetts and an affiliate of Harvard Medical School.

12 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

11 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

Enterprise marketing software provider Neolane, Inc. today announced that it has been selected by digital marketing and events solution company Cramer to support more effective marketing communications programs for its clients, specifically in its healthcare practice. The first program to benefit from Neolane's comprehensive, flexible marketing automation platform is a Cramer biopharmaceutical client that was seeking to improve the results of an on-going patient communications program that relies on targeted, personalized communications across multiple channels to support patient therapy.

11 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Immunomedics receives additional patent for CD74 target

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.

11 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Sinobiopharma, Inc., an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

Omeros net loss for second-quarter 2010 increases to $7.8 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and six months ended June 30, 2010.

11 Aug 2010

Biopharmaceutical News and Research

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

Hana Biosciences second-quarter net loss decreases to $6.3 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Intellect Neurosciences receives patent for insulin sensitizer drugs

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Immunomedics receives additional patent for CD74 target

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

Omeros net loss for second-quarter 2010 increases to $7.8 million

Pittcon Highlights: Pharmaceutical & Biologic eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News